Direct-to-Consumer (DTC) Advertising
Amgen’s mission is to serve patients, and that includes providing accurate information about diseases and medicines.
Responsible direct-to-consumer (DTC) advertising can play a role in increasing awareness about diseases, educating patients about treatment options, and fostering dialogue between patients and their healthcare providers. We have a responsibility to consider and evaluate on an ongoing basis the most appropriate settings for where and when we employ DTC advertising as an avenue to reach patients.
In our product advertising, we present risk information prominently, clearly and in simple consumer language. We test our advertising to ensure both our benefit and risk messages are successfully communicated.
Amgen also recognizes that patients and consumers can benefit from greater transparency and education about access to medicines, including the potential costs and resources that may help patients with the cost of their medicine. Amgen supports a proactive, consumer-oriented approach focused on providing information about a medicine’s price, including potential out-of-pocket costs, and Amgen-sponsored financial assistance that might be available. Effective April 2019, the list price has been added to our DTC product websites to help patients make more informed decisions about their health care. The example shown below is from our website for Aimovig®.
In addition, Amgen has voluntarily adopted the Pharmaceutical Research and Manufacturers of America (PhRMA) strengthened Guiding Principles on Direct to Consumer Advertisements about Prescription Medicines
For more information about how patients can access their medicines, please visit https://www.amgenassist360.com .
DTC advertising is only part of Amgen’s patient education effort. Amgen has long served patients, physicians, and communities by supporting a variety of health education programs singularly or with partnerships with patient advocacy groups or healthcare providers.